ZA9710560B - Percutaneous delivery system. - Google Patents

Percutaneous delivery system.

Info

Publication number
ZA9710560B
ZA9710560B ZA9710560A ZA9710560A ZA9710560B ZA 9710560 B ZA9710560 B ZA 9710560B ZA 9710560 A ZA9710560 A ZA 9710560A ZA 9710560 A ZA9710560 A ZA 9710560A ZA 9710560 B ZA9710560 B ZA 9710560B
Authority
ZA
South Africa
Prior art keywords
percutaneous delivery
physiologically active
delivery system
rate
delivery
Prior art date
Application number
ZA9710560A
Other languages
English (en)
Inventor
Rod Tomlinson
Greg Davey
Original Assignee
Soltec Res Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Soltec Res Pty Ltd filed Critical Soltec Res Pty Ltd
Publication of ZA9710560B publication Critical patent/ZA9710560B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7015—Drug-containing film-forming compositions, e.g. spray-on
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Virology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
ZA9710560A 1996-11-22 1997-11-24 Percutaneous delivery system. ZA9710560B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AUPO3795A AUPO379596A0 (en) 1996-11-22 1996-11-22 Percutaneous delivery system

Publications (1)

Publication Number Publication Date
ZA9710560B true ZA9710560B (en) 1998-06-10

Family

ID=3798105

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA9710560A ZA9710560B (en) 1996-11-22 1997-11-24 Percutaneous delivery system.

Country Status (19)

Country Link
US (1) US6211250B1 (sk)
EP (1) EP0944398B1 (sk)
JP (2) JP4358305B2 (sk)
KR (1) KR100551930B1 (sk)
AT (1) ATE263577T1 (sk)
AU (2) AUPO379596A0 (sk)
CA (1) CA2271139C (sk)
CZ (1) CZ289152B6 (sk)
DE (1) DE69728556T2 (sk)
DK (1) DK0944398T3 (sk)
ES (1) ES2219758T3 (sk)
HU (1) HU225586B1 (sk)
NO (1) NO322899B1 (sk)
PL (1) PL191824B1 (sk)
PT (1) PT944398E (sk)
RS (1) RS49900B (sk)
SK (1) SK284135B6 (sk)
WO (1) WO1998023291A1 (sk)
ZA (1) ZA9710560B (sk)

Families Citing this family (126)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9504265D0 (en) * 1995-03-03 1995-04-19 Medeva Plc Corticosteroid-containing pharmaceutical composition
AUPN814496A0 (en) * 1996-02-19 1996-03-14 Monash University Dermal penetration enhancer
AUPO983897A0 (en) 1997-10-17 1997-11-06 Soltec Research Pty Ltd Topical antifungal composition
AUPP310798A0 (en) * 1998-04-22 1998-05-14 Soltec Research Pty Ltd Vehicle system for a composition comprising a piperidinopyrimidine derivative
WO2000010540A1 (en) * 1998-08-20 2000-03-02 3M Innovative Properties Company Spray on bandage and drug delivery system
US6962691B1 (en) 1999-05-20 2005-11-08 U & I Pharmaceuticals Ltd. Topical spray compositions
US6228354B1 (en) * 1999-07-02 2001-05-08 Allegiance Corporation Water resistant film-forming antimicrobial skin-preparation
US6528086B2 (en) * 1999-09-28 2003-03-04 Zars, Inc. Methods and apparatus for drug delivery involving phase changing formulations
US20030044432A1 (en) * 2000-09-29 2003-03-06 Manetta Vincent E. Acne treating composition
DE60130917T2 (de) * 2000-12-21 2008-07-17 Alrise Biosystems Gmbh Induziertes phasenübergangsverfahren zur herstellung von hydrophile wirkstoffe enthaltenden mikropartikeln
US6528076B2 (en) 2001-07-06 2003-03-04 Magic Herb Corp. Topical compositions and methods for treating pain
US8501202B2 (en) * 2001-07-09 2013-08-06 Aqua Pharmaceuticals, Llc Sulfacetamide formulations for treatment of skin dermatoses
US8435942B2 (en) * 2002-05-31 2013-05-07 Transdermal Biotechnology, Inc. Methods for formulating stabilized insulin compositions
US20040018237A1 (en) * 2002-05-31 2004-01-29 Perricone Nicholas V. Topical drug delivery using phosphatidylcholine
NZ537359A (en) * 2002-06-25 2006-10-27 Cosmeceutic Solutions Pty Ltd Topical cosmetic compositions for transdermal delivery
NZ537360A (en) * 2002-06-25 2006-09-29 Acrux Dds Pty Ltd Transdermal delivery rate control using amorphous pharmaceutical compositions
US20050186141A1 (en) * 2002-06-25 2005-08-25 Acrux Dds Pty Ltd. Transdermal aerosol compositions
AU2002950506A0 (en) * 2002-07-31 2002-09-12 Soltec Research Pty Ltd Percutaneous delivery system
IL152486A0 (en) 2002-10-25 2003-05-29 Meir Eini Alcohol-free cosmetic and pharmaceutical foam carrier
WO2004037225A2 (en) 2002-10-25 2004-05-06 Foamix Ltd. Cosmetic and pharmaceutical foam
US10117812B2 (en) 2002-10-25 2018-11-06 Foamix Pharmaceuticals Ltd. Foamable composition combining a polar solvent and a hydrophobic carrier
US8900554B2 (en) 2002-10-25 2014-12-02 Foamix Pharmaceuticals Ltd. Foamable composition and uses thereof
US9668972B2 (en) 2002-10-25 2017-06-06 Foamix Pharmaceuticals Ltd. Nonsteroidal immunomodulating kit and composition and uses thereof
US7704518B2 (en) 2003-08-04 2010-04-27 Foamix, Ltd. Foamable vehicle and pharmaceutical compositions thereof
US20080138296A1 (en) 2002-10-25 2008-06-12 Foamix Ltd. Foam prepared from nanoemulsions and uses
US9265725B2 (en) 2002-10-25 2016-02-23 Foamix Pharmaceuticals Ltd. Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof
US9211259B2 (en) 2002-11-29 2015-12-15 Foamix Pharmaceuticals Ltd. Antibiotic kit and composition and uses thereof
US7700076B2 (en) 2002-10-25 2010-04-20 Foamix, Ltd. Penetrating pharmaceutical foam
US7820145B2 (en) 2003-08-04 2010-10-26 Foamix Ltd. Oleaginous pharmaceutical and cosmetic foam
ES2637956T3 (es) 2003-01-24 2017-10-18 Stiefel Research Australia Pty Ltd Espuma farmacéutica
US7871818B2 (en) * 2003-01-31 2011-01-18 Roche Madison Inc. Membrane active polymers
US7186416B2 (en) * 2003-05-28 2007-03-06 Stiefel Laboratories, Inc. Foamable pharmaceutical compositions and methods for treating a disorder
EP1498133A1 (en) 2003-07-18 2005-01-19 Aventis Pharma Deutschland GmbH Use of a pak inhibitor for the treatment of a joint disease
US8795693B2 (en) 2003-08-04 2014-08-05 Foamix Ltd. Compositions with modulating agents
EP1531333A1 (en) 2003-11-12 2005-05-18 Aventis Pharma Deutschland GmbH Method for the identification of a risk for a thrombogenic disorder by determining the TAFI-lle347 polymorphism
DE102004019916A1 (de) * 2004-04-21 2005-11-17 Grünenthal GmbH Gegen Missbrauch gesichertes wirkstoffhaltiges Pflaster
ES2442386T3 (es) 2004-04-23 2014-02-11 Bundesrepublik Deutschland Letztvertreten Durch Das Robert Koch-Institut Vertreten Durch Seinen Pr Método para el tratamiento de condiciones mediadas por células T por la disminución de las células positivas de ICOS in vivo.
US20080019927A1 (en) * 2004-06-07 2008-01-24 Jie Zhang Compositions and methods for dermally treating neuropathy with minoxidil
US20070190124A1 (en) * 2004-06-07 2007-08-16 Jie Zhang Two or more solidifying agent-containing compositions and methods for dermal delivery of drugs
US20070196457A1 (en) * 2004-06-07 2007-08-23 Jie Zhang Two or more volatile solvent-containing compositions and methods for dermal delivery of drugs
US8741332B2 (en) * 2004-06-07 2014-06-03 Nuvo Research Inc. Compositions and methods for dermally treating neuropathic pain
US20070196453A1 (en) * 2004-06-07 2007-08-23 Jie Zhang Two or more non-volatile solvent-containing compositions and methods for dermal delivery of drugs
US20070189978A1 (en) * 2004-06-07 2007-08-16 Jie Zhang Compositions and methods for dermally treating musculoskeletal pain
US20070196452A1 (en) * 2004-06-07 2007-08-23 Jie Zhang Flux-enabling compositions and methods for dermal delivery of drugs
US20070196323A1 (en) * 2004-06-07 2007-08-23 Jie Zhang Polyvinyl alcohol-containing compositions and methods for dermal delivery of drugs
US8741333B2 (en) 2004-06-07 2014-06-03 Nuvo Research Inc. Compositions and methods for treating dermatitis or psoriasis
US20070196325A1 (en) * 2004-06-07 2007-08-23 Jie Zhang Compositions and methods for dermally treating infections
US8907153B2 (en) * 2004-06-07 2014-12-09 Nuvo Research Inc. Adhesive peel-forming formulations for dermal delivery of drugs and methods of using the same
US20070196293A1 (en) * 2004-06-07 2007-08-23 Jie Zhang Compositions and methods for treating photo damaged skin
WO2006065991A2 (en) * 2004-12-17 2006-06-22 Dr. Reddy's Laboratories Ltd. Dispersion for delivering active agents
AU2006222204B2 (en) 2005-03-11 2012-09-27 Sanofi-Aventis Use of MGC4504
NZ563946A (en) * 2005-06-03 2012-02-24 Acrux Dds Pty Ltd Testosterone containing non-occlusive transdermal drug delivery composition for application to the arm pit / axilla
AU2006254742C1 (en) * 2005-06-03 2011-11-03 Acrux Dds Pty Ltd Method and composition for transdermal drug delivery
US8053000B2 (en) 2005-06-07 2011-11-08 Dr. Reddy's Laboratories Limited Compositions for drug delivery
EP1915117A2 (en) * 2005-07-28 2008-04-30 MacroChem Corporation Method for retarding systemic delivery rate for easily absorbable active agents
BRPI0616765A2 (pt) * 2005-09-29 2011-06-28 Novartis Ag composição antifúngica tópica adaptada para tratar uma infecção fúngica da pele, método para tratar uma infecção da pele por dermatófito, método para tratar infecção da pele e processo para a fabricação de uma composição farmacêutica tópica
CN101262848B (zh) * 2005-09-29 2011-05-11 诺瓦提斯公司 抗真菌组合物
DE102005048898A1 (de) 2005-10-12 2007-04-19 Sanofi-Aventis Deutschland Gmbh EGLN2-Varianten und ihre Verwendung bei der Vorbeugung oder Behandlung thromboembolischer Erkrankungen und koronarer Herzerkrankungen
EP1795609A1 (en) 2005-12-06 2007-06-13 Sanofi-Aventis Deutschland GmbH Method for the diagnosis and treatment of cardiovascular diseases
KR101368107B1 (ko) 2006-03-31 2014-03-14 스티펠 리서치 오스트레일리아 피티와이 리미티드 발포성 현탁겔
US20070280972A1 (en) * 2006-04-25 2007-12-06 Zars, Inc. Adhesive solid gel-forming formulations for dermal drug delivery
CN101588791A (zh) 2006-10-17 2009-11-25 纽沃研究公司 双氯芬酸凝胶
DE102006049929B4 (de) * 2006-10-19 2012-03-08 Beiersdorf Ag Filmbildende Gelkomposition zur Wund- bzw. Hautpflege
US20080260655A1 (en) 2006-11-14 2008-10-23 Dov Tamarkin Substantially non-aqueous foamable petrolatum based pharmaceutical and cosmetic compositions and their uses
EP2097074A4 (en) * 2006-12-04 2013-05-01 Glaxosmithkline Llc TOPICAL PHARMACEUTICAL COMPOSITION
WO2008083423A1 (en) 2007-01-11 2008-07-17 Acrux Dds Pty Ltd Spreading implement
US8636982B2 (en) 2007-08-07 2014-01-28 Foamix Ltd. Wax foamable vehicle and pharmaceutical compositions thereof
CA2702830C (en) 2007-10-18 2017-02-28 Stiefel Research Australia Pty Ltd Topical glycopyrrolate formulations
WO2009069006A2 (en) 2007-11-30 2009-06-04 Foamix Ltd. Foam containing benzoyl peroxide
WO2009090495A2 (en) 2007-12-07 2009-07-23 Foamix Ltd. Oil and liquid silicone foamable carriers and formulations
EP2105742A1 (en) 2008-03-26 2009-09-30 Sanofi-Aventis Use of cathepsin C
AU2009264237B2 (en) 2008-06-27 2016-04-14 Meta-Iq Aps Inhibitors of carnitin-palmitoyl-transferase-1 for the treatment and prevention of disorders caused by delipidation of neural tissue
MX2011002568A (es) * 2008-09-10 2011-04-07 Novartis Ag Composiciones para administracion percutanea.
US9012477B2 (en) * 2009-01-06 2015-04-21 Nuvo Research Inc. Method of treating neuropathic pain
US8618164B2 (en) 2009-03-31 2013-12-31 Nuvo Research Inc. Treatment of pain with topical diclofenac compounds
WO2010125470A2 (en) 2009-04-28 2010-11-04 Foamix Ltd. Foamable vehicle and pharmaceutical compositions comprising aprotic polar solvents and uses thereof
CA2769677A1 (en) 2009-07-29 2011-02-03 Foamix Ltd. Non surface active agent non polymeric agent hydro-alcoholic foamable compositions, breakable foams and their uses
WO2011013009A2 (en) 2009-07-29 2011-02-03 Foamix Ltd. Non surfactant hydro-alcoholic foamable compositions, breakable foams and their uses
EP2293072A1 (en) 2009-08-31 2011-03-09 Sanofi-Aventis Use of cathepsin H
US9849142B2 (en) 2009-10-02 2017-12-26 Foamix Pharmaceuticals Ltd. Methods for accelerated return of skin integrity and for the treatment of impetigo
WO2011064631A1 (en) 2009-10-02 2011-06-03 Foamix Ltd. Surfactant-free, water-free, foamable compositions and breakable foams and their uses
MX2012008168A (es) 2010-01-14 2013-02-07 Nuvo Res Inc Formulaciones anestesicas locales que forman solidos para control del dolor.
EP2444067A1 (en) 2010-10-20 2012-04-25 Laboratorios Ojer Pharma S.L. Anhydrous gel comprising mupirocin
CA2719512A1 (en) 2010-11-01 2012-05-01 Stiefel Research Australia Pty Ltd Polymeric topical compositions
TW201241179A (en) 2010-12-17 2012-10-16 Sanofi Sa MiRNAs in joint disease
TW201238974A (en) 2010-12-17 2012-10-01 Sanofi Sa MiRNAs in joint disease
TW201238973A (en) 2010-12-17 2012-10-01 Sanofi Sa MiRNAs in joint disease
TW201239097A (en) 2010-12-17 2012-10-01 Sanofi Sa MiRNAs in joint disease
CA2830298C (en) 2011-03-17 2016-08-16 Transdermal Biotechnology, Inc. Topical nitric oxide systems comprising lecithin and methods of use thereof
BR112013030365A2 (pt) * 2011-05-26 2016-11-29 Novartis Ag composições para administração percutânea de princípio ativo fisiologicamente
US8871254B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Systems and methods for treatment of acne vulgaris and other conditions with a topical nitric oxide delivery system
US8871261B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Cancer treatments and compositions for use thereof
US8871259B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Techniques and systems for treatment of neuropathic pain and other indications
US8871255B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Treatment of skin and soft tissue infection with nitric oxide
US8871262B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Compositions and methods for treatment of osteoporosis and other indications
US8871256B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Methods and systems for treatment of inflammatory diseases with nitric oxide
US8871260B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Methods and compositions for muscular and neuromuscular diseases
US8871257B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Prevention and treatment of cardiovascular diseases using systems and methods for transdermal nitric oxide delivery
US8871258B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Treatment and prevention of learning and memory disorders
KR101457789B1 (ko) 2013-02-13 2014-11-03 동아제약 주식회사 상처 치료용 필름형성 약제학적 조성물 및 그의 제조방법
US9849160B2 (en) 2013-03-13 2017-12-26 Transdermal Biotechnology, Inc. Methods and systems for treating or preventing cancer
US9314423B2 (en) 2013-03-13 2016-04-19 Transdermal Biotechnology, Inc. Hair treatment systems and methods using peptides and other compositions
US9724419B2 (en) 2013-03-13 2017-08-08 Transdermal Biotechnology, Inc. Peptide systems and methods for metabolic conditions
US9750787B2 (en) 2013-03-13 2017-09-05 Transdermal Biotechnology, Inc. Memory or learning improvement using peptide and other compositions
US9320706B2 (en) 2013-03-13 2016-04-26 Transdermal Biotechnology, Inc. Immune modulation using peptides and other compositions
US20140271731A1 (en) 2013-03-13 2014-09-18 Transdermal Biotechnology, Inc. Cardiovascular disease treatment and prevention
US9295637B2 (en) 2013-03-13 2016-03-29 Transdermal Biotechnology, Inc. Compositions and methods for affecting mood states
US9320758B2 (en) 2013-03-13 2016-04-26 Transdermal Biotechnology, Inc. Brain and neural treatments comprising peptides and other compositions
US9314433B2 (en) 2013-03-13 2016-04-19 Transdermal Biotechnology, Inc. Methods and systems for treating or preventing cancer
US9241899B2 (en) 2013-03-13 2016-01-26 Transdermal Biotechnology, Inc. Topical systems and methods for treating sexual dysfunction
US20140271937A1 (en) 2013-03-13 2014-09-18 Transdermal Biotechnology, Inc. Brain and neural treatments comprising peptides and other compositions
US9295647B2 (en) 2013-03-13 2016-03-29 Transdermal Biotechnology, Inc. Systems and methods for delivery of peptides
US9295636B2 (en) 2013-03-13 2016-03-29 Transdermal Biotechnology, Inc. Wound healing using topical systems and methods
US9339457B2 (en) 2013-03-13 2016-05-17 Transdermal Biotechnology, Inc. Cardiovascular disease treatment and prevention
US9393265B2 (en) 2013-03-13 2016-07-19 Transdermal Biotechnology, Inc. Wound healing using topical systems and methods
US9687520B2 (en) 2013-03-13 2017-06-27 Transdermal Biotechnology, Inc. Memory or learning improvement using peptide and other compositions
US9314417B2 (en) 2013-03-13 2016-04-19 Transdermal Biotechnology, Inc. Treatment of skin, including aging skin, to improve appearance
US9314422B2 (en) 2013-03-13 2016-04-19 Transdermal Biotechnology, Inc. Peptide systems and methods for metabolic conditions
US20140271938A1 (en) 2013-03-13 2014-09-18 Transdermal Biotechnology, Inc. Systems and methods for delivery of peptides
US9387159B2 (en) 2013-03-13 2016-07-12 Transdermal Biotechnology, Inc. Treatment of skin, including aging skin, to improve appearance
US9393264B2 (en) 2013-03-13 2016-07-19 Transdermal Biotechnology, Inc. Immune modulation using peptides and other compositions
USD750788S1 (en) 2013-11-26 2016-03-01 Acrux Dds Pty Ltd Topical spreading applicator
USD749225S1 (en) 2013-11-26 2016-02-09 Acrux Dds Pty Ltd Topical spreading applicator
TW201629140A (zh) 2015-02-09 2016-08-16 Genepharm Biotech Corp 可成膜的凝膠組成物
KR101580077B1 (ko) * 2015-03-28 2015-12-24 한국콜마주식회사 시크로피록스 함유 네일락카 조성물
US10398641B2 (en) 2016-09-08 2019-09-03 Foamix Pharmaceuticals Ltd. Compositions and methods for treating rosacea and acne

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4675009A (en) * 1977-11-07 1987-06-23 Lec Tec Corporation Drug dispensing device for transdermal delivery of medicaments
GB2075837B (en) 1980-05-14 1984-03-14 Hisamitsu Pharmaceutical Co Topical pharmaceutical gel containing anti-inflammatory analgesic agents
US4713244A (en) * 1985-08-16 1987-12-15 Bausch & Lomb Incorporated Sustained-release formulation containing an amino acid polymer with a lower alkyl (C1 -C4) polar solvent
JPH01503281A (ja) * 1987-05-27 1989-11-09 ブルグハルト，クルト 経皮治療に有効な医薬包帯剤およびこれを施用するためのデバイス
US4954332A (en) 1987-10-22 1990-09-04 The Procter & Gamble Company Photoprotection compositions comprising tocopherol sorbate and an anti-inflammatory agent
JPH0818983B2 (ja) * 1987-12-08 1996-02-28 塩野義製薬株式会社 水虫治療剤
EP0319988A1 (en) * 1987-12-09 1989-06-14 Showa Denko Kabushiki Kaisha External dermatological composition
US5081157A (en) 1988-05-02 1992-01-14 Zila Pharmaceuticals, Inc. Compositions and in situ methods for forming films on body tissue
US4940579A (en) 1988-12-27 1990-07-10 Minnesota Mining And Manufacturing Company Topical application of medicament in a binder
US5674912A (en) 1991-03-01 1997-10-07 Warner-Lambert Company Sunscreen-wound healing compositions and methods for preparing and using same
JP2671248B2 (ja) * 1991-10-23 1997-10-29 ブロック・ドラッグ・カンパニー・インコーポレイテッド 薬効または化粧効果成分の浸透性増進方法
CA2122271C (en) 1991-11-25 1998-06-23 Roy L. Blank Use of salicylic acid for regulating skin wrinkles and/or skin atrophy
IL105748A0 (en) * 1992-05-22 1993-09-22 Int Research & Dev Corp Topical antiperspirant composition
US5304368A (en) 1993-02-19 1994-04-19 American Telecast Corporation Non-foaming, non-viscous, alcohol-free, water-based, pressurized hair spray product
US5436241A (en) 1994-01-14 1995-07-25 Bristol-Myers Squibb Company Topical anti-inflammatory compositions containing piroxicam
WO1995030409A1 (en) * 1994-05-05 1995-11-16 Merck Frosst Canada Inc. Topical polymeric drug delivery system
FR2732223B1 (fr) * 1995-03-30 1997-06-13 Sanofi Sa Composition pharmaceutique pour administration transdermique

Also Published As

Publication number Publication date
HUP9903792A2 (hu) 2000-03-28
JP2008247912A (ja) 2008-10-16
ES2219758T3 (es) 2004-12-01
NO992290L (no) 1999-07-14
JP2001504499A (ja) 2001-04-03
NO322899B1 (no) 2006-12-18
JP4358305B2 (ja) 2009-11-04
PL191824B1 (pl) 2006-07-31
EP0944398A1 (en) 1999-09-29
DE69728556D1 (de) 2004-05-13
DK0944398T3 (da) 2004-08-02
CA2271139C (en) 2008-03-11
RS49900B (sr) 2008-08-07
CA2271139A1 (en) 1998-06-04
AU723143B2 (en) 2000-08-17
PT944398E (pt) 2004-07-30
SK284135B6 (sk) 2004-09-08
KR100551930B1 (ko) 2006-02-16
KR20000069044A (ko) 2000-11-25
EP0944398B1 (en) 2004-04-07
HUP9903792A3 (en) 2000-05-29
AU4936797A (en) 1998-06-22
CZ289152B6 (cs) 2001-11-14
AUPO379596A0 (en) 1996-12-19
YU22699A (sh) 2002-06-19
ATE263577T1 (de) 2004-04-15
WO1998023291A1 (en) 1998-06-04
DE69728556T2 (de) 2005-02-24
NO992290D0 (no) 1999-05-11
CZ181299A3 (cs) 1999-10-13
US6211250B1 (en) 2001-04-03
AU723143C (en) 2005-01-27
HU225586B1 (en) 2007-03-28
SK64599A3 (en) 2000-06-12
EP0944398A4 (en) 2000-07-19

Similar Documents

Publication Publication Date Title
ZA9710560B (en) Percutaneous delivery system.
WO1998037872A3 (en) Transdermal drug delivery system for the administration of tamsulosin, and related compositions and methods of use
GEP20043375B (en) APRIL-Receptor (BCMA) and Use Thereof
MXPA01012336A (es) Gel de silicon que contiene acido salicilico.
ZA961067B (en) Personal care compositions and wipe products containing the compositions
NO971192L (no) Fremgangsmåter for avlevering av materialer inn i huden, og sammensetninger som blir anvendt
FI962154A0 (fi) Koostumus terapeuttisten tuotteiden in vivo valmistusta varten
MY111188A (en) Improvements in or relating to benzothiophenes.
EP0943328A3 (en) Combination therapy for prophylaxis and/or treatment of benign prostatic hyperplasia
MX9602656A (es) Dispositivo transdermico que contiene pirrolidona polivinilica como mejorador de solubilidad.
HUT67046A (en) Enhanced skin penetration system for imporoved topical delivery of drugs
EP0993831A3 (en) Compounds and compositions for delivering active agents
IL111365A0 (en) (r)-5-carbamoyl -8-fluoro-3-n, n-disubstituted-amino-3, 4-dihydro-2h-1- benzopyrans
WO1999002133A3 (en) Topical application of a combination of benzoyl peroxide and a second active ingredient
HUP9601035A2 (en) Dihydropyridazinone and pyridazinone derivatives, use thereof, and fungicide and insecticide compositions containing these compounds as active ingredients
AU1890295A (en) Piperidines and pyrrolidines
MX9710252A (es) Utilizacion de al menos un peptido en una composicion cosmetica o para la preparacion de un medicamento.
AU3868997A (en) Pharmaceutical composition containing osteogenesis-promoting substance and a polyethylene glycol
AU2162700A (en) Supramolecular complexes containing therapeutic agents
LT96094A (en) The active ingredient of pharmaceutical composition for treating constipation
DK1092427T3 (da) Anvendelse af et peptid, der forebygger hudintolerancereaktioner, især i kosmetiske præparater
ATE204169T1 (de) Polyamin-antagonisten enthaltende intraokulare irrigationslösung
MX9800697A (es) Uso de glicosidos de calendula para el tratamiento de psoriasis.